Welcome to hubXchange’s Philadelphia Antibody Therapeutics Xchange 2024, bringing together executives from pharma and biotech to address and find solutions to the key issues faced in developing antibody therapeutics, through a series of roundtable discussions.
Discussion topics will cover Target Selection, Lead Identification & Optimization, Formats & Scaffolds, Bi/Multi-Specifics and Emerging Technologies.
Take advantage of this unique highly interactive meeting format designed for maximum engagement and collaboration with your peers.
Please note this is an In-Person meeting.
VENUE DETAILS:
Doubletree by Hilton Philadelphia Airport,
4509 Island Avenue,
Philadelphia, PA, 19153, US
SNAPSHOTS OF DISCUSSION TOPICS
- Different criteria for target selection depending on the type of biologic modality
- Difficult targets: how to screen and prioritize candidates
- Next generation antibodies addressing the road blocks for first generations
- Challenges of using single domain antibodies as new modalities of multifunctional biologics
- Novel technology to improve antibody access into solid tumors by using targeted enzymes
- Bispecific Antibodies for T-cell Redirection
- Novel delivery modes for biologics – beyond parenteral administration and beyond classical protein administration
- Emerging antibody based immune targets and technologies
Full Xchange Agenda
Target Selection
Opening Address & Keynote Presentation by Nona Biosciences
Integrated Services of ADC Discovery and Development
- Fully human antibody discovery using Harbour Mice
- ADC Discovery including both well-known and novel linker payload and various conjugation methods.
- In vitro and in vivo evaluation of ADC including binding, affinity, internalization, cytotoxicity, plasma stability, PK, efficacy, and toxicology studies, etc
Joe holds a BS from Fudan University and a PhD from University of Delaware, followed by postdoctoral trainings at Lankenau Medical Research Center and Zeneca Pharmaceuticals. Prior to joining Harbour BioMed, he was in small biotechs (Pharmacopeia and Ligand Pharmaceuticals) and large MNC (BMS). Joe has 25 years of combined experience in drug discovery of both small molecules and biologics in therapeutic areas of immuno-oncology, immunology, and genetic diseases.
Spotlight Presentation by WuXi Biologics
Innovative Platforms for Rapid and Cost-Effective HTP Antibody & Protein Production
As the field of biologics development advances, the demand for efficient, high-throughput (HTP) antibody and protein production grows. This talk showcases innovative HTP antibody and protein production platforms: Ultra 96+, 777, Quick ‘n’ Clean, Mini Protein Line and T Cell Mate, all powered by our ultra-high titer transient CHO system. These platforms are designed for rapid, cost-effective HTP production across various drug targets, from mAb to bsAb to new modalities like mini proteins and soluble TCRs. Each platform addresses specific challenges at different stages of drug discovery, expediting your drug development process.
Julia Su is an accomplished scientist and industry expert with a Ph.D. from Louisianan State University and post-doctoral training at the University of Washington. With over a decade of research experience in mRNA vaccines, gene cell therapy, and immunotherapy, Dr. Su possesses a robust technical background and a fervent passion for scientific discovery. Within WuXi Biologics’ Protein Sciences Department, she is renowned for her proficiency in protein and antibody production, adept at translating scientific innovations into practical solutions.
Paul Royle is the technical sales manager for Bio-Rad’s Custom Antibody Service (HuCAL®) and has been with Bio-Rad’s antibody division for over 10 years. Prior to this he worked in an immunology diagnostics company for almost 7 years. Paul holds a degree and PhD from the University of Nottingham (UK), and has post-doctoral research experience from the University of Warwick (UK).
